OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD) Files An 8-K Financial Statements and ExhibitsItem 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
Exhibit Number |
Exhibit Description |
|
10.1 |
Amendment to Marketing Authorization Holder Agreement between Oxford Immunotec Ltd. and Riken Genesis Co., Ltd. entered into July 24, 2017 |
EXHIBIT INDEX
|
Exhibit Number |
Exhibit Description |
|
10.1 |
Amendment to Marketing Authorization Holder Agreement between Oxford Immunotec Ltd. and Riken Genesis Co., Ltd. entered into July 24, 2017 |
Oxford Immunotec Global PLC ExhibitEX-10.1 2 ex10-1.htm EXHIBIT 10.1 ex10-1.htm Exhibit 10.1 AMENDMENT TO MARKETING AUTHORIZATION HOLDER AGREEMENT (“Amendment 3”) This Amendment (“Amendment 3”) is made this July 7th,…To view the full exhibit click here
About OXFORD IMMUNOTEC GLOBAL PLC (NASDAQ:OXFD)
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Its development activities are principally focused on approximately four areas: chronic infections; transplantation; autoimmune and inflammatory disease, and immune-oncology. The Company’s autoimmune and inflammatory disease programs include its SpiroFind assay, targeting Lyme disease; GoutiFind, targeting gout, and Stratokine, targeting efficacy of biologic therapies. Its T-SPOT.TB test is used to test for Tuberculosis (TB) infection. Its T-SPOT.CMV assay is used to assess the strength of a patient’s cellular immune response to cytomegalovirus (CMV), infection. It is also developing T-SPOT.PRT and T-SPOT.ICA.
